로딩 중…
지수 로딩 중…
GI Innovation
358570· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩11,550-8.19%
2026-06-19
Price Chart
GI Innovation-51.27%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 742.22B KRW |
| Revenue | 5.63B KRW |
| Net Income | -34.65B KRW |
| Total Assets | 116.12B KRW |
| Net Assets | 107.80B KRW |
| Employees | 84 |
| Value | |
| P/B | 6.89x |
| P/S | 131.93x |
| FCF Yield | -5.35% |
| Profitability | |
| ROE | -32.14% |
| ROA | -29.84% |
| Op. Margin | -731.84% |
| Revenue Growth | -100.00% |
| Financial Health | |
| Debt Ratio | 107.72% |
| Total Debt | 1.65B KRW |
| FCF | -39.68B KRW |
| Cash | 24.82B KRW |
| Current Ratio | 4.69x |
| Performance | |
| 1Y Return | -51.27% |
| 1M Return | 11.49% |
| From 52W High | -53.61% |
| 1Y MDD | -56.83% |
| Trading | |
| Volume | 1,104,287 shares |
| Foreign Own. | 5.77% |
| Per Share | |
| EPS | -546 KRW |
| BPS | 1,678 KRW |
Company Info
GI Innovation, established in 2017, is a specialized fusion protein-based new drug research and development company that listed on KOSDAQ under special provisions in 2023. It boasts a diverse pipeline of immune therapeutics, including immuno-oncology drugs and allergy treatments, facilitated by its GI-SMART platform technology for one-stop early discovery. The company has completed technology transfers to Simcere and Yuhan Corporation and entered into a joint clinical trial agreement with MSD, contributing to the creation of a global innovative new drug pipeline. GI Innovation is headquartered in Songpa-gu, Seoul.